To further validate if RB1 inactivation would lead to neuroendocrine phenotype transformation in the shRB cells, we conducted immunocytochemistry in shRB group vs shNC group with synaptophysin (Syn) and chromogranin A (CgA) antibodies, the two commonly clinical markers for SCLC. This evidence concerns the gene SYP and small cell lung carcinoma.